Abstract
Background: Once the optimal dose is reached, subcutaneous immunotherapy [SCIT] with mite extract is capable of reducing symptoms and the need for rescue medication. Objective: To assess the capacity of a subcutaneous extract of mites [D. pteronyssinus] to bring about a reduction in concomitant medication as well as in vivo and in vitro changes in just 2-3 months of treatment in patients with allergic asthma. Methods: A total of 45 patients with persistent mildmoderate allergic asthma due to sensitisation to D. pteronyssinus were included in a multi-centre, double-blind, placebocontrolled trial. Length of treatment was 4 months. After a period for adjusting medication in order to classify asthma severity appropriately, patients were commenced on treatment of 400 or 800 μg/day of budesonide as concomitant medication. Results: After 4 months of treatment there were no significant changes in the budesonide dose between the active group and the placebo group. In the active group there was a significant difference between active and placebo group in sIgG4 [p=.0003], as well as a significant increase in the cutaneous tolerance index [2.81, CI 95%: 1.29 – 7.48, which was significant with a Confidence Interval of 95%]. These changes were not observed in the placebo group. Conclusion: After just 4 months of treatment, SCIT was capable of inducing in vivo and in vitro changes, but these changes were not reflected in improved clinical outcome within the first 4 months of therapy.
Keywords: Allergic asthma, dermatophagoides pteronyssinus, specific IgG4, short-term effect, skin-prick test, subcutaneous immunotherapy
Current Drug Delivery
Title: Assessment of Short-Term Changes Induced by a Dermatophagoides pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial
Volume: 8 Issue: 2
Author(s): Carmen Vidal, Ana I. Tabar, Javier Figueroa, Jose A. Navarro, Cesarea Sanchez, Agustin Orovitg, Margarita Armisen, Susana Echechipia, Alejandro Joral, Susana Lizarza, Mª Teresa Lizaso, Virginia Rodriguez and Fernando de la Torre
Affiliation:
Keywords: Allergic asthma, dermatophagoides pteronyssinus, specific IgG4, short-term effect, skin-prick test, subcutaneous immunotherapy
Abstract: Background: Once the optimal dose is reached, subcutaneous immunotherapy [SCIT] with mite extract is capable of reducing symptoms and the need for rescue medication. Objective: To assess the capacity of a subcutaneous extract of mites [D. pteronyssinus] to bring about a reduction in concomitant medication as well as in vivo and in vitro changes in just 2-3 months of treatment in patients with allergic asthma. Methods: A total of 45 patients with persistent mildmoderate allergic asthma due to sensitisation to D. pteronyssinus were included in a multi-centre, double-blind, placebocontrolled trial. Length of treatment was 4 months. After a period for adjusting medication in order to classify asthma severity appropriately, patients were commenced on treatment of 400 or 800 μg/day of budesonide as concomitant medication. Results: After 4 months of treatment there were no significant changes in the budesonide dose between the active group and the placebo group. In the active group there was a significant difference between active and placebo group in sIgG4 [p=.0003], as well as a significant increase in the cutaneous tolerance index [2.81, CI 95%: 1.29 – 7.48, which was significant with a Confidence Interval of 95%]. These changes were not observed in the placebo group. Conclusion: After just 4 months of treatment, SCIT was capable of inducing in vivo and in vitro changes, but these changes were not reflected in improved clinical outcome within the first 4 months of therapy.
Export Options
About this article
Cite this article as:
Vidal Carmen, I. Tabar Ana, Figueroa Javier, A. Navarro Jose, Sanchez Cesarea, Orovitg Agustin, Armisen Margarita, Echechipia Susana, Joral Alejandro, Lizarza Susana, Teresa Lizaso Mª, Rodriguez Virginia and de la Torre Fernando, Assessment of Short-Term Changes Induced by a Dermatophagoides pteronyssinus Extract on Asthmatic Patients. Randomised, Double-Blind, Placebo-Controlled Trial, Current Drug Delivery 2011; 8 (2) . https://dx.doi.org/10.2174/156720111794479871
DOI https://dx.doi.org/10.2174/156720111794479871 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Cytokines and Inflammation in Catecholamine-Induced Pulmonary Injury in Rats
Vascular Disease Prevention (Discontinued) Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Clinical Pharmacology of Novel Anti-Alzheimer Disease Modifying Medications
Current Topics in Medicinal Chemistry Novel 1,2,4-Triazolo[3,4-b]-1,3,4-thiadiazole Derivatives as Dual Analgesic/Anti-inflammatory and Antimicrobial Agents
Letters in Drug Design & Discovery Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Systematic Review of the Serotonergic System in the Pathophysiology of Severe Dengue: The Theory of Thrombocytopenia and Vascular Extravasation
Mini-Reviews in Medicinal Chemistry Piper sarmentosum Roxb. Root Extracts Confer Neuroprotection by Attenuating Beta Amyloid-Induced Pro-Inflammatory Cytokines Released from Microglial Cells
Current Alzheimer Research Protein Glycation: An Old Villain is Shedding Secrets
Combinatorial Chemistry & High Throughput Screening Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein
Current Protein & Peptide Science Safety Considerations in the Use of Ketorolac for Postoperative Pain
Current Drug Safety Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Neutrophil Proteome: Lessons from Different Standpoints
Protein & Peptide Letters Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Novel Pharmacologic Strategies to Protect the Liver from Ischemia- Reperfusion Injury
Recent Patents on Cardiovascular Drug Discovery Peak and Trough Concentrations of Gentamicin in the Neonate: A Review of the Literature
Current Pediatric Reviews Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics